Outcomes of proton therapy to infradiaphragmatic sites in pediatric patients with Hodgkin lymphoma

Author:

Jiang Cecilia1ORCID,Kim Michele1,Han Xiaoyan2,Chelius Monica1,Hoover Travis3,Kersun Leslie4,Reilly Anne F.45,Hubbeling Harper1,Cummings Elizabeth1,Kurtz Goldie1,Hill‐Kayser Christine1,Plastaras John P.1ORCID,LaRiviere Michael J.1

Affiliation:

1. Department of Radiation Oncology University of Pennsylvania Philadelphia Pennsylvania USA

2. Department of Biostatics, Epidemiology, and Informatics Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

3. Department of Radiation Oncology University of Maryland Baltimore Maryland USA

4. Division of Oncology The Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

5. Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

Abstract

AbstractBackgroundProton therapy (PT) has potential advantages in pediatric Hodgkin lymphoma (pHL). However, there are limited data on PT, specifically to infradiaphragmatic targets. We report on PT planning details, doses achieved to organs at risk (OARs), and clinical and toxicity outcomes for patients with pHL who received PT to infradiaphragmatic regions.MethodsThis is a retrospective study including patients treated between 2011 and 2022. Demographic and clinical factors were collected, and toxicity was reported using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Dosimetric and clinical factors associated with key outcomes were assessed via Cox regression. Photon plans were generated for all patients, and the paired t‐tests or Wilcoxon signed rank sum tests were used for dosimetric comparisons.ResultsTwenty‐one patients comprising 22 PT courses were included. Median follow‐up was 5.0 years, and mean age was 14.2 years. Median dose was 21 Gray equivalent (GyE) over 14 fractions. Top acute grade 1 (G1) toxicities included fatigue (59%) and anorexia (36%). Rates of acute G2 and G3+ toxicity were 18% and 0%, respectively. After PT, no local or marginal failures occurred. Five percent experienced disease progression, who were all successfully salvaged, and all patients were alive and disease‐free at last follow‐up. No secondary malignancies developed. Compared to photon radiotherapy, PT achieved significantly lower doses to the bowels, stomach, spleen, pancreatic tail, liver, kidneys, and pelvic bones.ConclusionsPT is well‐tolerated and leads to excellent oncologic and toxicity outcomes with long‐term follow‐up. PT confers dosimetric advantages when compared to photons.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3